T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

A. Ott, Patrick; Bang, Yung‐Jue; A. Piha‐Paul, Sarina; R. Abdul Razak, Albiruni; Bennouna, Jaafar; Soria, Jean‐Charles; S. Rugo, Hope; B. Cohen, Roger; H. O’Neil, Bert; M. Mehnert, Janice; Lopez, Juanita; Doi, Toshihiko; M.J. van Brummelen, Emilie; Cristescu, Răzvan; Yang, Ping; Emancipator, Kenneth; Stein, Karen; Ayers, Mark; K. Joe, Andrew; Lunceford, Jared

doi:10.1200/jco.2018.78.2276

Public

T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

Published in Journal of Clinical Oncology • Dec 17, 2018

Authors:

Patrick A. Ott

Yung‐Jue Bang

Sarina A. Piha‐Paul

Abstract

PURPOSE: Biomarkers that can predict response to anti-programmed cell death 1 (PD-1) therapy across multiple tumor types include a T-cell-inflamed gene-expression profile (GEP), programmed death ligand 1 (PD-L1) expression, and tumor mutational burden (TMB). Associations between these biomarkers and...

Subject

Pembrolizumab

Medicine

Internal medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!